Skip to main
PCVX
PCVX logo

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. is positioned for a positive outlook primarily due to the superior immunological performance of its product candidates, particularly VAX-24 and VAX-31, which have shown improved immune responses compared to existing vaccines like PCV20. The ongoing clinical studies suggest a strong potential for VAX-24 in initiating robust seroresponse rates in infants and maintaining a leadership position in the next-generation pneumococcal vaccine market, with projections indicating a potential global revenue opportunity exceeding $7-10 billion. Furthermore, the favorable clinical data emerging from both adult and infant trials could enhance investor confidence and significantly elevate Vaxcyte's market valuation in the coming years.

Bears say

The negative outlook on Vaxcyte Inc. is primarily rooted in several significant risks, including the potential for unforeseen delays in research and development, disappointing clinical results regarding efficacy and safety, and slower than anticipated commercial uptake, all of which could hinder the company's growth prospects. Additionally, the company faces fierce competition, with the possibility that rival programs may advance more swiftly, further complicating Vaxcyte’s market position. Finally, the ongoing anti-vaccine sentiment poses a macro-level challenge, potentially exacerbating the company's share price volatility and limiting the long-term viability of its vaccine products, even if they successfully pass clinical trials.

Vaxcyte (PCVX) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $122.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $122.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.